Maya Epifanova

Maya Epifanova

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2019 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
MEMaya Epifanova
Maya Epifanova
BGBadri R. Gvasalia
Badri R. Gvasalia
MDMaksim A. Durashov
Maksim A. Durashov
SASergey A. Artemenko
Sergey A. Artemenko
Introduction: Platelet-rich plasma (PRP) found its use in treating different conditions and diseases, because concentrated plasma PRP consists of many growth factors. Their interaction with surrounding cells, intracellular matrix, and mediators at the site of injection leads to tissue regeneration. Angiogenic, vasculogenic, and regenerative effects of PRP may be used for erectile dysfunction (ED) and Peyronie’s disease (PD) treatment.Aim: To present a current data review of preclinical and clinical trials on PRP use for treating ED and PD.Methods: Up-to-date literature on PRP use for ED and PD treatment was analyzed. The search was based on Pubmed, Cochrane Library, clinicaltrials.gov databases, with the following key words: “platelet-rich plasma” and/or “erectile dysfunction” and/or “Peyronie’s disease” and/or “sexual dysfunction.”Main Outcome Measures: The main outcome measures for preclinical trials on ED were erectile function, assessed with intracavernous pressure, and pathologic analysis of penile tissue. The main outcome measures for clinical trials on ED included penile duplex Doppler ultrasound scanning and validated questionnaires. The main outcome measures on PD were pathologic analysis of penile tissue for preclinical trials, as well as penile duplex Doppler ultrasound scanning, penile curvature angle measuring, and validated questionnaires for clinical trials.Results: 4 preclinical and 6 clinical trials were described and analyzed in this article. Limitations for both preclinical and clinical trials included small groups, short follow-up periods, a lack of control groups or groups with placebo, and the lack of quality and quantity analysis of PRP.Conclusion: Available data show the lack of adverse reactions with PRP treatment. The studies that we found were limited by small groups. This is why the data on safety and effectiveness should be taken carefully. However, it is important to mention that PRP therapy has the potential for treating male sexual dysfunction and may be useful in andrology.

17 December 2015
Verified
Journal Article
Closed access
MCM E Chalyj
M E Chalyj
VGV A Grigorjan
V A Grigorjan
MEMaya Epifanova
Maya Epifanova
AKA O Krasnov
A O Krasnov

18 March 2022 in Andrology and Genital Surgery
Verified
Journal Article
Open access
PDF file
MEMaya Epifanova
Maya Epifanova
АKА. А. Kostin
А. А. Kostin
EGE. V. Gameeva
E. V. Gameeva
SAS. A. Artemenko
S. A. Artemenko
АEА. А. Epifanov
А. А. Epifanov
Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT). The study objective was to evaluate the effectiveness of ESWT in the treatment of CP. Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age. Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p 0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p 0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA. Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora.

8 January 2023 in Andrology and Genital Surgery
Verified
Journal Article
Open access
PDF file
MEMaya Epifanova
Maya Epifanova
AKA. A. Kostin
A. A. Kostin
EGE. V. Gameeva
E. V. Gameeva
ESE. V. Slavkina
E. V. Slavkina
SAS. A. Artemenko
S. A. Artemenko
AEA. A. Epifanov
A. A. Epifanov
Применение экстракорпоральной ударно-волновой терапии в сочетании с другими немедикаментозными методами при лечении хронического простатита с позиций современной доказательной медицины


1 December 2017
Verified
Journal Article
Closed access
MEMaya Epifanova
Maya Epifanova
MCM E Chalyi
M E Chalyi
BGB R Gvasaliya
B R Gvasaliya
IEI I Eremin
I I Eremin
APAndrey Pulin
Andrey Pulin
ARA M Repin
A M Repin